Literature DB >> 3616282

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews.

R Collins, R Gray, J Godwin, R Peto.   

Abstract

In order to avoid selective biases and to minimize random errors, inference about the effects of treatment on serious endpoints needs to be based not on one, or a few, of the available trial results, but on a systematic overview of the totality of the evidence from all the relevant unconfounded randomized trials. But, only where coverage of all, or nearly all, randomized patients in all relevant trials (or a reasonably unbiased sample of such trials) can be assured, is a systematic overview of trials reasonably trustworthy, for then any selective biases are likely to be small in comparison with any moderate effects of treatment. Checks for the existence of such biases can best be conducted if reasonably detailed data are available from each trial. Future trials should take into account the results of any relevant overviews in their design, and should plan to obtain sufficient numbers of events to contribute substantially to such overviews. In many cases, this implies the need for randomized trials that are much larger than is currently standard.

Entities:  

Mesh:

Year:  1987        PMID: 3616282     DOI: 10.1002/sim.4780060308

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  21 in total

Review 1.  Surgical interventions for glue ear: what form will a quality service take?

Authors:  T A Sheldon; N Freemantle; F Song; J M Mason; A F Long; T Thakker; D Addshead
Journal:  Qual Health Care       Date:  1992-12

2.  Meta-analyses in cancer clinical trials: principles and pitfalls.

Authors:  J R Benson; K Saeb-Parsy
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Audit of attitudes to and use of postoperative thromboembolic prophylaxis in a regional health authority.

Authors:  D R Jones
Journal:  Ann R Coll Surg Engl       Date:  1991-07       Impact factor: 1.891

Review 4.  Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Authors:  Alina Andras; Adriano Sala Tenna; Marlene Stewart
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

Review 5.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.

Authors:  Lindsay Robertson; Lauren E Jones
Journal:  Cochrane Database Syst Rev       Date:  2017-02-09

Review 6.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

8.  Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.

Authors:  R Collins; S MacMahon; M Flather; C Baigent; L Remvig; S Mortensen; P Appleby; J Godwin; S Yusuf; R Peto
Journal:  BMJ       Date:  1996-09-14

9.  British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction.

Authors:  R Collins; D Julian
Journal:  Br Heart J       Date:  1991-09

Review 10.  Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence.

Authors:  Koon K Teo; Salim Yusuf
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.